{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:48:51Z","timestamp":1776235731836,"version":"3.50.1"},"reference-count":314,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) caused by chronic inflammation. It is the leading cause of neurologic symptoms in young people and leads to progressive neurodegenerative disability. Accumulating evidence indicates that MS arises from the coordinated and co-dominant actions of peripheral immune cells, meningeal tertiary lymphoid structures (TLS), and CNS-resident immune compartments. Within this complex immunopathological network, dysregulated T-cell-mediated adaptive immune responses play a pivotal role in initiating and organizing autoimmune inflammation. Peripherally activated T cells cross the blood-brain barrier (BBB), become reactivated within the CNS, and secrete pro-inflammatory cytokines that drive demyelination and neurodegeneration. Improved understanding of these immune mechanisms has led to the development of disease-modifying therapies (DMTs), many of which directly or indirectly target T-cell function. Here, we adopt a T-cell-centric perspective to systematically review the pathogenic mechanisms of MS, with particular emphasis on recent advances and unresolved questions regarding T-cell subset dysregulation, systematically integrating its precise targeting associations with conventional disease-modifying therapies (DMTs). Simultaneously, the mechanisms of emerging therapies were analyzed, and the potential of traditional herbal medicines was explored. This approach overcomes the limitations of previous studies that focused solely on a single T cell subset or a single therapeutic category.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1740656","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:46:24Z","timestamp":1776231984000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhimei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Immunology, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghe","family":"Han","sequence":"additional","affiliation":[{"name":"Dalian University Affiliated Xinhua Hospital","place":["Dalian, Liaoning, China"]},{"name":"Department of Anatomy, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xikai","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangping","family":"Liu","sequence":"additional","affiliation":[{"name":"Engineering Technology Research Center for the Utilization of Functional Components of Organic Natural Products, Dalian University","place":["Dalian, Liaoning, China"]},{"name":"Institute of Marine Traditional Chinese Medicine","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihua","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical College, Dalian University","place":["Dalian, Liaoning, China"]},{"name":"Institute of Marine Traditional Chinese Medicine","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Medical College, Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076354","article-title":"Sex and gender differences in neurodegenerative diseases: Challenges for therapeutic opportunities","volume":"24","author":"Bianco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200388","article-title":"White matter tract degeneration in multiple sclerosis patients with progression independent of relapse activity","volume":"12","author":"Ocampo-Pineda","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac111","article-title":"Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study","volume":"145","author":"Portaccio","year":"2022","journal-title":"Brain"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00415-025-13322-7","article-title":"Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study","volume":"272","author":"Ahmad","year":"2025","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: molecular pathogenesis and therapeutic intervention","volume":"10","author":"Boutitah-Benyaich","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123426","article-title":"Effects of rhythmic-cued gait training on gait-like task related brain activation in people with multiple sclerosis","volume":"471","author":"Helmlinger","year":"2025","journal-title":"J Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02355-4","article-title":"Visual dysfunction in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis: a review","volume":"58","author":"Shin","year":"2021","journal-title":"Mol Neurobiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231174580","article-title":"Intravesical injections of botulinum neurotoxin A to treat overactive bladder and\/or detrusor overactivity related to multiple sclerosis: 5-year continuation rate and specific risk factors for discontinuation-a study from the neuro-urology committee of the French Association of Urology","volume":"29","author":"Delaval","year":"2023","journal-title":"Mult Scler"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2450788","article-title":"An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis","volume":"25","author":"De Meo","year":"2025","journal-title":"Expert Rev Neurother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22074\/cellj.2016.4867","article-title":"Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","article-title":"The neuropathobiology of multiple sclerosis","volume":"25","author":"Woo","year":"2024","journal-title":"Nat Rev Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.05.025","article-title":"Neurodegeneration and demyelination in multiple sclerosis","volume":"112","author":"Garton","year":"2024","journal-title":"Neuron"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200004","article-title":"Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis","volume":"9","author":"von Essen","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.10.014","article-title":"Tertiary lymphoid structures in the central nervous system","volume":"31","author":"Yang","year":"2025","journal-title":"Trends Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12841","article-title":"B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis","volume":"30","author":"Reali","year":"2020","journal-title":"Brain Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41467-019-14118-w","article-title":"Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis","volume":"11","author":"Schafflick","year":"2020","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlw063","article-title":"ROR\u03b3t expression and lymphoid neogenesis in the brain of patients with secondary progressive multiple sclerosis","volume":"75","author":"Serafini","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt110","article-title":"Disease-specific molecular events in cortical multiple sclerosis lesions","volume":"136","author":"Fischer","year":"2013","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70045","article-title":"Follicle on the roof: Tertiary lymphoid structures in central nervous system autoimmunity","volume":"332","author":"Zuo","year":"2025","journal-title":"Immunol Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124558","article-title":"Neutrophils: Underestimated players in the pathogenesis of multiple sclerosis (MS)","volume":"21","author":"De Bondt","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3265029","article-title":"Correlation between the neutrophil-to-lymphocyte ratio and multiple sclerosis: Recent understanding and potential application perspectives","volume":"2022","author":"Zhou","year":"2022","journal-title":"Neurol Res Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cells13020150","article-title":"Involvement of astrocytes in the formation, maintenance, and function of the blood-brain barrier","volume":"13","author":"Schiera","year":"2024","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlad046","article-title":"Microglia subtypes in acute, subacute, and chronic multiple sclerosis","volume":"82","author":"Prineas","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/ijms24031861","article-title":"Role of microglial cells in the pathophysiology of MS: Synergistic or antagonistic","volume":"24","author":"Mado","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte crosstalk in CNS inflammation","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"key":"B32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/cells13110921","article-title":"Neurodegenerative diseases: Unraveling the heterogeneity of astrocytes","volume":"13","author":"Santiago-Balmaseda","year":"2024","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.ai.2021.03.002","article-title":"Modeling a complex disease: Multiple sclerosis-update 2020","volume":"149","author":"Regen","year":"2021","journal-title":"Adv Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025813118","article-title":"Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation","volume":"118","author":"Larochelle","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01006-1","article-title":"Assessing disease progression and treatment response in progressive multiple sclerosis","volume":"20","author":"Comi","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cells9020482","article-title":"T helper cells: The modulators of inflammation in multiple sclerosis","volume":"9","author":"Kunkl","year":"2020","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996469","article-title":"Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2024.09.004","article-title":"Cathepsin C exacerbates EAE by promoting the expansion of Tfh cells and the formation of TLSs in the CNS","volume":"123","author":"Liu","year":"2025","journal-title":"Brain Behav Immun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1101379","article-title":"The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis","volume":"17","author":"Angelini","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl6157","article-title":"Tissue-resident CD8(+) T cells drive compartmentalized and chronic autoimmune damage against CNS neurons","volume":"14","author":"Frieser","year":"2022","journal-title":"Sci Transl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl6058","article-title":"Tissue-resident memory CD8(+) T cells cooperate with CD4(+) T cells to drive compartmentalized immunopathology in the CNS","volume":"14","author":"Vincenti","year":"2022","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00753","article-title":"Th1 and Th17 cells and associated cytokines discriminate among clinically isolated syndrome and multiple sclerosis phenotypes","volume":"8","author":"Arellano","year":"2017","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112056","article-title":"Heterogeneity of human CD4(+) T cells against microbes","volume":"34","author":"Sallusto","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03056","article-title":"Intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 differentially contribute to peripheral activation and CNS entry of autoaggressive Th1 and Th17 cells in experimental autoimmune encephalomyelitis","volume":"10","author":"Haghayegh Jahromi","year":"2019","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0486-8","article-title":"ADAM12 is a costimulatory molecule that determines Th1 cell fate and mediates tissue inflammation","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12974-020-01861-x","article-title":"The impact of regional astrocyte interferon-\u03b3 signaling during chronic autoimmunity: a novel role for the immunoproteasome","volume":"17","author":"Smith","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-023-02917-4","article-title":"Astrocyte interferon-gamma signaling dampens inflammation during chronic central nervous system autoimmunity via PD-L1","volume":"20","author":"Smith","year":"2023","journal-title":"J Neuroinflamm"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2025.103149","article-title":"Context matters: Conflicting roles of interferon-\u03b3 signaling in CNS diseases","volume":"96","author":"Nulman","year":"2025","journal-title":"Curr Opin Neurobiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.01.007","article-title":"Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system","volume":"46","author":"Spath","year":"2017","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912583","article-title":"Transcription factor RUNX3 mediates plasticity of ThGM cells toward Th1 phenotype","volume":"13","author":"Rasouli","year":"2022","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba9953","article-title":"A distinct GM-CSF(+) T helper cell subset requires T-bet to adopt a T(H)1 phenotype and promote neuroinflammation","volume":"5","author":"Rasouli","year":"2020","journal-title":"Sci Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822919","article-title":"T(H) cells and cytokines in encephalitogenic disorders","volume":"13","author":"Krishnarajah","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13325","article-title":"Relapsing\/remitting multiple sclerosis: A speculative model and its implications for a novel treatment","volume":"98","author":"Bretscher","year":"2023","journal-title":"Scand J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2021-0296","article-title":"Construction of a lncRNA-miRNA-mRNA network to determine the key regulators of the Th1\/Th2 imbalance in multiple sclerosis","volume":"13","author":"Azari","year":"2021","journal-title":"Epigenomics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11481-019-09852-3","article-title":"Dopaminergic therapeutics in multiple sclerosis: Focus on Th17-cell functions","volume":"15","author":"Melnikov","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00415","article-title":"The phosphorylation of CCR6 on distinct Ser\/Thr residues in the carboxyl terminus differentially regulates biological function","volume":"9","author":"Lu","year":"2018","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210262","article-title":"Trojan horse nanocapsule enabled in situ modulation of the phenotypic conversion of Th17 cells to Treg cells for the treatment of multiple sclerosis in mice","volume":"35","author":"Shi","year":"2023","journal-title":"Adv Mater"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/jci155693","article-title":"microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance","volume":"132","author":"Fujiwara","year":"2022","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.immuni.2024.09.017","article-title":"Transcription factor TCF1 binds to ROR\u03b3t and orchestrates a regulatory network that determines homeostatic Th17 cell state","volume":"57","author":"Mangani","year":"2024","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932152","article-title":"Th17 cells and inflammation in neurological disorders: Possible mechanisms of action","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01535-9","article-title":"Th17 cell pathogenicity in autoimmune disease","volume":"57","author":"Park","year":"2025","journal-title":"Exp Mol Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ana.21748","article-title":"Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis","volume":"66","author":"Kebir","year":"2009","journal-title":"Ann Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2027","article-title":"ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1774","article-title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","volume":"10","author":"Zhou","year":"2009","journal-title":"Nat Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"El-Behi","year":"2011","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3109\/08923979809034820","article-title":"Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity","volume":"20","author":"Carrieri","year":"1998","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403243","article-title":"Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-\u03b2 therapy","volume":"194","author":"Rasouli","year":"2015","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817473","article-title":"Chemokine-driven migration of pro-inflammatory CD4(+) T cells in CNS autoimmune disease","volume":"13","author":"Heng","year":"2022","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0473","article-title":"DICAM promotes T(H)17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation","volume":"14","author":"Charabati","year":"2022","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.065","article-title":"Inflammatory Th17 cells express integrin \u03b1v\u03b23 for pathogenic function","volume":"16","author":"Du","year":"2016","journal-title":"Cell Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7597","article-title":"Integrin \u03b13 promotes T(H)17 cell polarization and extravasation during autoimmune neuroinflammation","volume":"8","author":"Park","year":"2023","journal-title":"Sci Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-141978","article-title":"Cellular mechanisms of IL-17-induced blood-brain barrier disruption","volume":"24","author":"Huppert","year":"2010","journal-title":"FASEB J"},{"key":"B76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jneuroim.2015.11.022","article-title":"B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses","volume":"291","author":"Ireland","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12974-017-0978-3","article-title":"Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties","volume":"14","author":"Prajeeth","year":"2017","journal-title":"J Neuroinflamm"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970508","article-title":"Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"B80","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12967-022-03570-w","article-title":"Dual roles of interleukin-33 in cognitive function by regulating central nervous system inflammation","volume":"20","author":"Rao","year":"2022","journal-title":"J Transl Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.brainres.2011.02.045","article-title":"Production and functions of IL-33 in the central nervous system","volume":"1385","author":"Yasuoka","year":"2011","journal-title":"Brain Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/bs.ai.2022.10.001","article-title":"T cells in the brain inflammation","volume":"157","author":"Yoshimura","year":"2023","journal-title":"Adv Immunol"},{"key":"B83","article-title":"Numerical status of CD4(+)CD25(+)FoxP3(+) and CD8(+)CD28(-) regulatory T cells in multiple sclerosis","volume":"17","author":"Kouchaki","year":"2014","journal-title":"Iran J Basic Med Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"10476","DOI":"10.1038\/s41598-021-88448-5","article-title":"Multiple sclerosis patients have reduced resting and increased activated CD4(+)CD25(+)FOXP3(+)T regulatory cells","volume":"11","author":"Verma","year":"2021","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp1720","article-title":"An autoimmune transcriptional circuit drives FOXP3(+) regulatory T cell dysfunction","volume":"16","author":"Sumida","year":"2024","journal-title":"Sci Transl Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1729690","article-title":"Metabolic regulation of regulatory T cells: mechanisms, heterogeneity, and implications in disease","volume":"16","author":"Getachew","year":"2025","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948470","article-title":"Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer","volume":"50","author":"Kurniawan","year":"2020","journal-title":"Eur J Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091282","article-title":"DNA methylation in regulatory T cell differentiation and function: Challenges and opportunities","volume":"12","author":"Bai","year":"2022","journal-title":"Biomolecules"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5393894","article-title":"CD4(+) T cell fate in glomerulonephritis: A tale of Th1, Th17, and novel Treg subtypes","volume":"2016","author":"Krebs","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002980","article-title":"Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT","volume":"1","author":"Gartlan","year":"2017","journal-title":"Blood Adv"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.824411","article-title":"Astrocytes and inflammatory T helper cells: A dangerous liaison in multiple sclerosis","volume":"13","author":"Kunkl","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200009","article-title":"Increased intrathecal activity of follicular helper T cells in patients with relapsing-remitting multiple sclerosis","volume":"9","author":"Holm Hansen","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200033","article-title":"Multiple sclerosis CSF is enriched with follicular T cells displaying a Th1\/Eomes signature","volume":"9","author":"Morille","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B94","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cei.13596","article-title":"Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis","volume":"205","author":"Haque","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178792","article-title":"T follicular helper cells and T follicular regulatory cells in autoimmune diseases","volume":"14","author":"Qi","year":"2023","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12974-021-02076-4","article-title":"Dysregulated follicular regulatory T cells and antibody responses exacerbate experimental autoimmune encephalomyelitis","volume":"18","author":"Luo","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518779951","article-title":"Peripheral imbalanced TFH\/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset","volume":"25","author":"Puthenparampil","year":"2019","journal-title":"Mult Scler"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4103\/1735-5362.343085","article-title":"Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls","volume":"17","author":"Yahyazadeh","year":"2022","journal-title":"Res Pharm Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.204110","article-title":"Neutralization of interleukin-9 decreasing mast cells infiltration in experimental autoimmune encephalomyelitis","volume":"130","author":"Yin","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2024.2364586","article-title":"The emerging role of T helper 9 (Th9) cells in immunopathophysiology: A comprehensive review of their effects and responsiveness in various disease states","volume":"43","author":"Khokhar","year":"2024","journal-title":"Int Rev Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015273","article-title":"Histamine H4 receptor antagonist ameliorates the progression of experimental autoimmune encephalomyelitis via regulation of T-cell imbalance","volume":"24","author":"Aldossari","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2015.07.010","article-title":"IL-9 signaling affects central nervous system resident cells during inflammatory stimuli","volume":"99","author":"Ding","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.113997","article-title":"Cathepsin B inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental autoimmune encephalomyelitis","volume":"351","author":"Ansari","year":"2022","journal-title":"Exp Neurol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900400","article-title":"IL-22 binding protein promotes the disease process in multiple sclerosis","volume":"203","author":"Lindahl","year":"2019","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.192.3.393","article-title":"Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction","volume":"192","author":"Babbe","year":"2000","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308689100","article-title":"Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood","volume":"101","author":"Skulina","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa352","article-title":"Tissue-resident CD8+ memory T cells in multiple sclerosis","volume":"144","author":"Hohlfeld","year":"2021","journal-title":"Brain"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/jci162788","article-title":"CD8+ T cells recognizing a neuron-restricted antigen injure axons in a model of multiple sclerosis","volume":"133","author":"Clarkson","year":"2023","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2020.05.023","article-title":"Immunosenescence: the role of age in multiple sclerosis","volume":"38","author":"Ostolaza Ib\u00e1\u00f1ez","year":"2023","journal-title":"Neurologia (Engl Ed)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103957","article-title":"Senescent CD4(+) T cells and autoimmune diseases: mechanisms and therapeutic prospects","volume":"25","author":"Hu","year":"2026","journal-title":"Autoimmun Rev"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104179","article-title":"Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age","volume":"82","author":"Zuroff","year":"2022","journal-title":"EBioMedicine"},{"key":"B113","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12974-025-03474-8","article-title":"Aging-dependent change in Th17 and cytokine response in multiple sclerosis","volume":"22","author":"Zhu","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001094","article-title":"Evaluation of age-dependent immune signatures in patients with multiple sclerosis","volume":"8","author":"Eschborn","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2023.08.002","article-title":"Advances in multiple sclerosis neurotherapeutics, neuroprotection, and risk mitigation strategies","volume":"42","author":"Abdelrahman","year":"2024","journal-title":"Neurol Clin"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015443.pub2","article-title":"Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis","volume":"9","author":"Ridley","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2024.2330642","article-title":"Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches","volume":"46","author":"Aliyu","year":"2024","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1026449","article-title":"The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement","volume":"13","author":"Raftopoulou","year":"2022","journal-title":"Front Neurol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp5802","article-title":"Type I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells","volume":"17","author":"Varghese","year":"2025","journal-title":"Sci Transl Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/jci33342","article-title":"The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice","volume":"118","author":"Guo","year":"2008","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679498","article-title":"IFN-\u03b2 acts on monocytes to ameliorate CNS autoimmunity by inhibiting proinflammatory cross-talk between monocytes and Th cells","volume":"12","author":"Rasouli","year":"2021","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.011","article-title":"Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system","volume":"28","author":"Prinz","year":"2008","journal-title":"Immunity"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000980","article-title":"B-cell activity predicts response to glatiramer acetate and interferon in relapsing-remitting multiple sclerosis","volume":"8","author":"Tacke","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578328","article-title":"Novel biomarkers and interferon signature in secondary progressive multiple sclerosis","volume":"389","author":"Fogel","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener Dis Manag"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.22034\/iji.2024.100500.2694","article-title":"The effect of interferon beta and natalizumab on miR-20b expression in patients with relapsing-remitting multiple sclerosis is potentially mediated by modulation of the Jak-STAT signaling pathway: a case-control study","volume":"21","author":"Jafari Harandi","year":"2024","journal-title":"Iran J Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.49.2.358","article-title":"Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"49","author":"Rudick","year":"1997","journal-title":"Neurology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40120-023-00565-7","article-title":"Twenty years of subcutaneous interferon-beta-1a for multiple sclerosis: contemporary perspectives","volume":"13","author":"Freedman","year":"2024","journal-title":"Neurol Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0568-2","article-title":"A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1212\/01.Wnl.0000158329.30470.D0","article-title":"Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c97ed3","article-title":"Monoclonal antibodies in MS: mechanisms of action","author":"Bielekova","year":"2010","journal-title":"Neurology"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann Neurol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25508","article-title":"Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis","volume":"86","author":"van Langelaar","year":"2019","journal-title":"Ann Neurol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.medj.2021.01.006","article-title":"Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis","volume":"2","author":"Kaufmann","year":"2021","journal-title":"Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01560","article-title":"Immune cell profiling during switching from natalizumab to fingolimod reveals differential effects on systemic immune-regulatory networks and on trafficking of non-T cell populations into the cerebrospinal fluid-results from the ToFingo Successor Study","volume":"9","author":"Lohmann","year":"2018","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000128136.79044.d6","article-title":"Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects","volume":"62","author":"O\u2019Connor","year":"2004","journal-title":"Neurology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251372752","article-title":"Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook","volume":"18","author":"Klotz","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00363","article-title":"Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: a propensity-matched study","volume":"21","author":"Chisari","year":"2024","journal-title":"Neurotherapeutics"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-335495","article-title":"Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials","volume":"96","author":"Dzau","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1575653","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"16","author":"Glenn","year":"2025","journal-title":"Front Neurol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108432","article-title":"Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis","volume":"246","author":"Kihara","year":"2023","journal-title":"Pharmacol Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7151685","article-title":"Enduring clinical value of Copaxone\u00ae (glatiramer acetate) in multiple sclerosis after 20 years of use","volume":"2019","author":"Wynn","year":"2019","journal-title":"Mult Scler Int"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.25","article-title":"Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis","volume":"12","author":"Johnson","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"B149","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3390\/ijms24010852","article-title":"Hepatotoxicity of drugs used in multiple sclerosis, diagnostic challenge, and the role of HLA genotype susceptibility","volume":"24","author":"Meunier","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.124.000927","article-title":"Glatiramer acetate for the treatment of multiple sclerosis: from first-generation therapy to elucidation of immunomodulation and repair","volume":"76","author":"Aharoni","year":"2024","journal-title":"Pharmacol Rev"},{"key":"B151","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.3390\/ijms24098447","article-title":"The role of BDNF in multiple sclerosis neuroinflammation","volume":"24","author":"Nociti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01535-8","article-title":"Insulin-like growth factor-1 receptor controls the function of CNS-resident macrophages and their contribution to neuroinflammation","volume":"11","author":"Ivan","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060159","article-title":"Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study","volume":"169","author":"Maier","year":"2006","journal-title":"Am J Pathol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf252","article-title":"Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor","volume":"125","author":"Ziemssen","year":"2002","journal-title":"Brain"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1159\/000532022","article-title":"Interferon Beta-1a versus Glatiramer Acetate: Changes of innate immunity in a group of women with multiple sclerosis","volume":"86","author":"Peterka","year":"2023","journal-title":"Eur Neurol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl043","article-title":"Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis","volume":"129","author":"Stasiolek","year":"2006","journal-title":"Brain"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211032323","article-title":"Effect of switching glatiramer acetate formulation from 20 mg daily to 40 mg three times weekly on immune function in multiple sclerosis","volume":"7","author":"Ito","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.6411","article-title":"Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression","volume":"180","author":"Venken","year":"2008","journal-title":"J Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000698","article-title":"Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS","volume":"7","author":"H\u00e4usler","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123620","article-title":"Novel liposomal glatiramer acetate: Preparation and immunomodulatory evaluation in murine model of multiple sclerosis","volume":"648","author":"Rahiman","year":"2023","journal-title":"Int J Pharm"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/ana.64.abs","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis","volume":"49","author":"Comi","year":"2001","journal-title":"Ann Neurol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102780","article-title":"Tolerability and acceptance of switching from brand to generic glatiramer acetate in multiple sclerosis","volume":"13","author":"Maraffi","year":"2024","journal-title":"J Clin Med"},{"key":"B163","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0404.2010.01444.x","article-title":"Pathophysiology of multiple sclerosis and the place of teriflunomide","volume":"124","author":"Gold","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009882.pub3","article-title":"Teriflunomide for multiple sclerosis","volume":"3","author":"He","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200251","article-title":"Alterations of thymus-derived Tregs in multiple sclerosis","volume":"11","author":"Lorenzini","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B166","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12974-024-03144-1","article-title":"Differences in the characteristics and functions of brain and spinal cord regulatory T cells","volume":"21","author":"Watanabe","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113476","article-title":"The emerging role of microglia in the development and therapy of multiple sclerosis","volume":"143","author":"Nan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100797","article-title":"Targeted therapy of multiple sclerosis: A case for antigen-specific Tregs","volume":"13","author":"Zhong","year":"2024","journal-title":"Cells"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104719","article-title":"Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis","volume":"75","author":"Wu","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-023-03655-7","article-title":"Teriflunomide promotes blood-brain barrier integrity by upregulating claudin-1 via the Wnt\/\u03b2-catenin signaling pathway in multiple sclerosis","volume":"61","author":"Zhao","year":"2024","journal-title":"Mol Neurobiol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm4459","article-title":"Engineered Wnt ligands enable blood-brain barrier repair in neurological disorders","volume":"375","author":"Martin","year":"2022","journal-title":"Science"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2247","article-title":"Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells","volume":"30","author":"Lippmann","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000291","article-title":"Induction of gut regulatory CD39(+) T cells by teriflunomide protects against EAE","volume":"3","author":"Ochoa-Rep\u00e1raz","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000403","article-title":"Teriflunomide treatment reduces B cells in patients with MS","volume":"4","author":"Gandoglia","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in pediatric multiple sclerosis (TERIKIDS): a multicenter, double-blind, phase 3, randomized, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241252722","article-title":"TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time","volume":"17","author":"Kallmann","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1264842","article-title":"Novel potential pharmacological applications of dimethyl fumarate-an overview and update","volume":"14","author":"Bresciani","year":"2023","journal-title":"Front Pharmacol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.07.001","article-title":"Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies","volume":"17","author":"Montes Diaz","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B181","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.msard.2018.04.016","article-title":"Dimethyl fumarate downregulates the immune response through the HCA(2)\/GPR109A pathway: Implications for the treatment of multiple sclerosis","volume":"23","author":"von Glehn","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040857","article-title":"Dimethyl fumarate suppresses demyelination and axonal loss through reduction in pro-inflammatory macrophage-induced reactive astrocytes and complement C3 deposition","volume":"10","author":"Yadav","year":"2021","journal-title":"J Clin Med"},{"key":"B183","doi-asserted-by":"publisher","first-page":"13146","DOI":"10.1038\/s41598-024-63877-0","article-title":"Myelin oligodendrocyte glycoprotein reactive Th17 cells drive Janus kinase 1 dependent transcriptional reprogramming in astrocytes and alter cell surface cytokine receptor profiles during experimental autoimmune encephalomyelitis","volume":"14","author":"Milne","year":"2024","journal-title":"Sci Rep"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1391949","article-title":"Dimethyl fumarate modulates the regulatory T cell response in the mesenteric lymph nodes of mice with experimental autoimmune encephalomyelitis","volume":"15","author":"Lima","year":"2024","journal-title":"Front Immunol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/acn3.270","article-title":"Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis","volume":"3","author":"Michell-Robinson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601532","article-title":"Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients","volume":"198","author":"Wu","year":"2017","journal-title":"J Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515608961","article-title":"Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients","volume":"22","author":"Longbrake","year":"2016","journal-title":"Mult Scler"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01039","article-title":"Genetic study of severe prolonged lymphopenia in multiple sclerosis patients treated with dimethyl fumarate","volume":"10","author":"Sangurdekar","year":"2019","journal-title":"Front Genet"},{"key":"B190","doi-asserted-by":"publisher","first-page":"895","DOI":"10.4103\/aian.aian_467_23","article-title":"Study to compare the efficacy and cost-effectiveness of various disease modifying drugs in the management of multiple sclerosis in India- an observational study","volume":"26","author":"Sehrawat","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMA Neurol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221132469","article-title":"Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate","volume":"8","author":"Lyons","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N Engl J Med"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: Results from the phase 3 EVOLVE-MS-1 study","volume":"39","author":"Wray","year":"2022","journal-title":"Adv Ther"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01397-5","article-title":"Real-world experience with diroximel fumarate in patients with multiple sclerosis: A prospective multicenter study","volume":"44","author":"Aguirre","year":"2024","journal-title":"Clin Drug Investig"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104469","article-title":"Clinical status and CNS adverse drug report of sphingosine-1-phosphate receptor modulators in multiple sclerosis","volume":"30","author":"Haldar","year":"2025","journal-title":"Drug Discov Today"},{"key":"B197","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: Beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: Insights from a pooled analysis of 15 randomized controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516991","article-title":"Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1021\/ml300396r","article-title":"Discovery of BAF312 (Siponimod), a potent and selective S1P receptor modulator","volume":"4","author":"Pan","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132058","article-title":"Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives","volume":"11","author":"Bravo","year":"2022","journal-title":"Cells"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1290666","article-title":"Bioavailable central nervous system disease-modifying therapies for multiple sclerosis","volume":"14","author":"Hartung","year":"2023","journal-title":"Front Immunol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review","volume":"11","author":"Coyle","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30239-x","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicenter, randomized, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomized, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multicenter trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01437-2","article-title":"Alemtuzumab: a review in relapsing remitting multiple sclerosis","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011203.pub3","article-title":"Alemtuzumab for multiple sclerosis","volume":"6","author":"Riera","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249201","article-title":"Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control","volume":"14","author":"von Essen","year":"2023","journal-title":"Front Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000194","article-title":"Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months","volume":"3","author":"De Mercanti","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301926","article-title":"Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis","volume":"191","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241306575","article-title":"Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study","volume":"18","author":"Ziemssen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211061335","article-title":"Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit\/risk following review of trial and post-marketing data","volume":"28","author":"Coles","year":"2022","journal-title":"Mult Scler"},{"key":"B220","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-024-03263-9","article-title":"The role of alemtuzumab in the development of secondary autoimmunity in multiple sclerosis: a systematic review","volume":"21","author":"Jimenez-Sanchez","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000208006","article-title":"Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study","volume":"102","author":"Ng","year":"2024","journal-title":"Neurology"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.119","article-title":"Cladribine - an old newcomer for pulsed immune reconstitution in MS","volume":"13","author":"Wiendl","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B223","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-246140","article-title":"Beyond hairy cell: the activity of cladribine in other hematologic Malignancies","volume":"116","author":"Sigal","year":"2010","journal-title":"Blood"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol Ther"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200048","article-title":"Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy","volume":"10","author":"Wiendl","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251342855","article-title":"Cladribine tablets in the new multiple sclerosis era","volume":"18","author":"Buttari","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512189","article-title":"Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study","volume":"16","author":"Wiendl","year":"2025","journal-title":"Front Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1327672","article-title":"Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine","volume":"15","author":"Holm Hansen","year":"2024","journal-title":"Front Immunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26684","article-title":"Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis","volume":"94","author":"Holm Hansen","year":"2023","journal-title":"Ann Neurol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1038\/s41598-023-34384-5","article-title":"Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment","volume":"13","author":"Kalatskaya","year":"2023","journal-title":"Sci Rep"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251351760","article-title":"Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study","volume":"18","author":"Schmierer","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B237","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40262-018-0706-x","article-title":"Correction to: The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis","volume":"58","author":"Hermann","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032011","article-title":"Oral therapies for multiple sclerosis","volume":"9","author":"Faissner","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.121.5.1121","article-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","volume":"121","author":"Bubien","year":"1993","journal-title":"J Cell Biol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS Drugs"},{"key":"B243","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann Neurol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B246","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00415-025-13297-5","article-title":"First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis","volume":"272","author":"Abbadessa","year":"2025","journal-title":"J Neurol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207291120","article-title":"Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity","volume":"120","author":"Shinoda","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells8010012","article-title":"Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients","volume":"8","author":"Gingele","year":"2018","journal-title":"Cells"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01182-8","article-title":"The evolution of anti-CD20 treatment for multiple sclerosis: Optimization of antibody characteristics and function","volume":"39","author":"Cree","year":"2025","journal-title":"CNS Drugs"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110266","article-title":"A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis","volume":"120","author":"Sabahi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201910_19314","article-title":"Curcumin prevents experimental autoimmune encephalomyelitis by inhibiting proliferation and effector CD4+ T cell activation","volume":"23","author":"Liu","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103274","article-title":"Prospective study to evaluate efficacy, safety and tolerability of dietary supplement of curcumin (BCM95) in subjects with active relapsing multiple sclerosis treated with subcutaneous interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial","volume":"56","author":"Petracca","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2008.10.015","article-title":"Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression","volume":"9","author":"Imler","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1080\/1028415x.2024.2425649","article-title":"Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial","volume":"28","author":"Keramatzadeh","year":"2025","journal-title":"Nutr Neurosci"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0964-2","article-title":"Green tea epigallocatechin-3-gallate modulates differentiation of na\u00efve CD4+ T cells into specific lineage effector cells","volume":"91","author":"Wang","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000981","article-title":"Epigallocatechin gallate in relapsing-remitting multiple sclerosis: A randomized, placebo-controlled trial","volume":"8","author":"Bellmann-Strobl","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B261","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2020.01.015","article-title":"Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities","volume":"80","author":"Efferth","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13406","article-title":"Exploring the immune-modulating properties of boswellic acid in experimental autoimmune encephalomyelitis","volume":"132","author":"Shadab","year":"2024","journal-title":"Apmis"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317101","article-title":"A standardized frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)","volume":"89","author":"St\u00fcrner","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109562","article-title":"The small-molecule compound baicalein alleviates experimental autoimmune encephalomyelitis by suppressing pathogenetic CXCR6(+) CD4 cells","volume":"114","author":"Ying","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1038\/srep41887","article-title":"Paeoniflorin ameliorates experimental autoimmune encephalomyelitis via inhibition of dendritic cell function and Th17 cell differentiation","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1461102","article-title":"CAR immunotherapy in autoimmune diseases: Promises and challenges","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003111","article-title":"Dawn of CAR-T cell therapy in autoimmune diseases","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B268","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: A novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"key":"B270","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00470-5","article-title":"CAR-T therapy for multiple sclerosis enters US trials for first time","author":"Mullard","year":"2024","journal-title":"Nature"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105681","article-title":"Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis","volume":"87","author":"Vaheb","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1517369","article-title":"Recent advances in mesenchymal stem cell therapy for multiple sclerosis: Clinical applications and challenges","volume":"13","author":"Sheikhi","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2024.102067","article-title":"Intraperitoneal injection of mesenchymal stem cells-conditioned media (MSCS-CM) treated monocyte can potentially alleviate motor defects in experimental autoimmune encephalomyelitis female mice; An original experimental study","volume":"85","author":"Jalali Kondori","year":"2024","journal-title":"Transpl Immunol"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.12171","article-title":"Adipose-derived mesenchymal stem cells ameliorates experimental autoimmune encephalomyelitis via modulation of Th1\/Th17 and expansion of Th2\/Treg responses","volume":"48","author":"Zargarani","year":"2024","journal-title":"Cell Biol Int"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696605","article-title":"Current understanding of IL-37 in human health and disease","volume":"12","author":"Su","year":"2021","journal-title":"Front Immunol"},{"key":"B277","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/s12967-024-05450-x","article-title":"Re-establishing immune tolerance in multiple sclerosis: Focusing on novel mechanisms of mesenchymal stem cell regulation of Th17\/Treg balance","volume":"22","author":"Hu","year":"2024","journal-title":"J Transl Med"},{"key":"B278","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.47435","article-title":"IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5\/IL-1R8","volume":"11","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2021","journal-title":"Theranostics"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1042\/cs20201544","article-title":"Murine endometrial-derived mesenchymal stem cells suppress experimental autoimmune encephalomyelitis depending on indoleamine-2,3-dioxygenase expression","volume":"135","author":"Manganeli Polonio","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03874.x","article-title":"Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells","volume":"156","author":"English","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.3390\/cells13121063","article-title":"Non-coding RNAs in neurological and neuropsychiatric disorders: Unraveling the hidden players in disease pathogenesis","volume":"13","author":"Ilieva","year":"2024","journal-title":"Cells"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042255","article-title":"Multiple sclerosis: Roles of miRNA, lcnRNA, and circRNA and their implications in cellular pathways","volume":"25","author":"Cipriano","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08051-8","article-title":"miRNAs in neurodegenerative diseases: From target screening to precision therapy","volume":"46","author":"Liao","year":"2025","journal-title":"Neurol Sci"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578100","article-title":"miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3","volume":"379","author":"Xue","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B285","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00602","article-title":"Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment","volume":"22","author":"Naydovich","year":"2025","journal-title":"Neurotherapeutics"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22803","article-title":"Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism","volume":"63","author":"Menzfeld","year":"2015","journal-title":"Glia"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02204-z","article-title":"Inhibition of Bruton\u2019s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease","volume":"140","author":"Torke","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02411-w","article-title":"BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: Implications for multiple sclerosis therapy","volume":"143","author":"Li","year":"2022","journal-title":"Acta Neuropathol"},{"key":"B290","doi-asserted-by":"publisher","first-page":"10116","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat Commun"},{"key":"B291","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00401-024-02730-0","article-title":"BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair","volume":"147","author":"Geladaris","year":"2024","journal-title":"Acta Neuropathol"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5332","article-title":"Targeting B cells and microglia in multiple sclerosis with Bruton tyrosine kinase inhibitors: A review","volume":"80","author":"Dybowski","year":"2023","journal-title":"JAMA Neurol"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): A multicenter, double-blind, randomized, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol"},{"key":"B294","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813957","article-title":"Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis: A review on behalf of the EBMT Autoimmune Diseases Working Party","volume":"12","author":"Cencioni","year":"2021","journal-title":"Front Immunol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann Neurol"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00834","article-title":"Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis","volume":"9","author":"Darlington","year":"2018","journal-title":"Front Immunol"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq1693","article-title":"Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"14","author":"Ruder","year":"2022","journal-title":"Sci Transl Med"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127655","article-title":"Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis","volume":"5","author":"Harris","year":"2020","journal-title":"JCI Insight"},{"key":"B301","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.27247","article-title":"Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: A single center cohort study","volume":"98","author":"Muraro","year":"2025","journal-title":"Ann Neurol"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2110","article-title":"T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat Med"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00301-x","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomized, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"Jama"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae260","article-title":"Serum biomarkers at disease onset for personalized therapy in multiple sclerosis","volume":"147","author":"Monreal","year":"2024","journal-title":"Brain"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"B307","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106694","article-title":"Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials","volume":"103","author":"Nahayati","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00389-x","article-title":"Autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis","volume":"11","author":"Nabizadeh","year":"2022","journal-title":"Neurol Ther"},{"key":"B311","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctim.2017.02.004","article-title":"Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis","volume":"31","author":"Song","year":"2017","journal-title":"Complement Ther Med"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0466-4","article-title":"Efficacy and tolerability of phytomedicines in multiple sclerosis patients: A review","volume":"31","author":"Farzaei","year":"2017","journal-title":"CNS Drugs"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1635833","article-title":"Efficacy and safety of Chinese herbal medicine for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Guan","year":"2025","journal-title":"Front Pharmacol"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116383","article-title":"Pharmacovigilance of herbal medicines: Concerns and future prospects","volume":"309","author":"Choudhury","year":"2023","journal-title":"J Ethnopharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1740656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:46:28Z","timestamp":1776231988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1740656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":314,"alternative-id":["10.3389\/fimmu.2026.1740656"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1740656","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1740656"}}